Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity.

AUTOR(ES)

Contreras, A M

RESUMO

We studied 113 patients treated with intravenous amikacin to determine the value of determining serial trough and peak amikacin levels in plasma for predicting nephrotoxicity. Thirteen patients (11.5%) developed renal toxicity, with significant increases from 48 to 96 h in both peak and trough amikacin levels (6.7 +/- 4.7 [standard deviation] days before the serum creatinine rose). The nontoxicity group had no change or even showed decrements in amikacin levels in plasma. A higher nephrotoxicity risk was seen in patients with increments greater than 1 microgram/ml between 48 and 96 h, with odds ratios of 16.4 for trough, 8 for peak, and 7.2 for both levels. We suggest that an increment of at least 1 microgram/ml in amikacin levels in plasma from 48 to 96 h may predict the appearance of renal toxicity.

Documentos Relacionados

• Assessment of urinary protein 1 and transferrin as early markers of cadmium nephrotoxicity.
• Vancomycin enhancement of experimental tobramycin nephrotoxicity.
• Renal transport of organic acids and bases in aminoglycoside nephrotoxicity.
• Ceftriaxone protects against tobramycin nephrotoxicity.
• Renal cadmium overload without nephrotoxicity.